These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

720 related items for PubMed ID: 31755111

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sensory Hypersensitivity Symptoms in Migraine With vs Without Aura: Results From the American Registry for Migraine Research.
    Pearl TA, Dumkrieger G, Chong CD, Dodick DW, Schwedt TJ.
    Headache; 2020 Mar; 60(3):506-514. PubMed ID: 31965576
    [Abstract] [Full Text] [Related]

  • 4. Impact of Depression and Anxiety Symptoms on Patient-Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR).
    Pearl TA, Dumkrieger G, Chong CD, Dodick DW, Schwedt TJ.
    Headache; 2020 Oct; 60(9):1910-1919. PubMed ID: 32749685
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study.
    Munjal S, Singh P, Reed ML, Fanning K, Schwedt TJ, Dodick DW, Buse DC, Lipton RB.
    Headache; 2020 Feb; 60(2):416-429. PubMed ID: 31837007
    [Abstract] [Full Text] [Related]

  • 7. A 3-month analysis of disability, quality of life, and disease course in patients with migraine.
    Raggi A, Leonardi M, Bussone G, D'Amico D.
    Headache; 2013 Feb; 53(2):297-309. PubMed ID: 23094760
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Wilcox TK, Shah S, Tepper SJ, Dodick DW, Lipton RB.
    Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
    [Abstract] [Full Text] [Related]

  • 12. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC, Serrano D, Reed ML, Kori SH, Cunanan CM, Adams AM, Lipton RB.
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [Abstract] [Full Text] [Related]

  • 13. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ.
    Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trial.
    Shao SC, Hentz J, Shank P, Leonard M, Dodick DW, Schwedt TJ.
    Headache; 2024 Jun; 64(6):632-642. PubMed ID: 38780360
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.
    Karlsson WK, Ashina H, Cullum CK, Christensen RH, Al-Khazali HM, Amin FM, Ashina M, REFORM Investigators.
    J Headache Pain; 2023 Jun 12; 24(1):70. PubMed ID: 37303034
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.